Lung Cancer Trial Data Readout to Arrive in 2027
The study evaluates new immunotherapy combinations for adults with unresectable Stage III non-small cell lung cancer.
Updated on Oct. 27, 2026 in Cancer
Live Poll
Is the new 2027 timeline for the PACIFIC-9 trial likely to remain the final readout date?
AstraZeneca has pushed the expected data readout for its PACIFIC-9 Phase 3 clinical trial to the first half of 2027. The trial evaluates immunotherapy combinations for patients with unresectable Stage III non-small cell lung cancer.
Why it matters
This trial investigates whether adding newer therapies to existing maintenance treatments can improve outcomes for patients who have not progressed after initial chemoradiation. The shift in timeline reflects the event-driven nature of the study, as researchers wait for sufficient clinical data to emerge.
The PACIFIC-9 trial is a Phase 3 study evaluating durvalumab in combination with either monalizumab or oleclumab for patients with unresectable Stage III non-small cell lung cancer. Enrollment for the trial is complete, though final results remain pending.
The players
AstraZeneca
A global biopharmaceutical company focusing on oncology, including research into immunotherapy treatments for lung cancer.
The details
The trial targets patients who have not progressed after completing platinum-based chemoradiation therapy. By pairing the immunotherapy durvalumab with monalizumab or oleclumab, researchers aim to determine if these combinations offer superior therapeutic benefits compared to current standard maintenance approaches. Because the study is event-driven, the timeline depends on the accumulation of clinical occurrences among participants, leading to the updated 2027 projection.
Timeline
October 2018: AstraZeneca obtained full oncology rights to monalizumab.
Second half of 2026: Previous expected timing for the trial data readout.
First half of 2027: Updated expected timing for the PACIFIC-9 data readout.
Health Landscape
The PACIFIC-9 study is part of an ongoing effort to evolve maintenance care for unresectable Stage III non-small cell lung cancer. It builds on the broader PACIFIC clinical trial program which explores how combining immunotherapy agents can potentially extend survival outcomes.
Patients and their families monitoring advancements in lung cancer therapy should note that this study's results are not expected until 2027. These developments are best discussed with an oncologist who can provide context on how emerging research may eventually affect future treatment options.
The takeaway
The PACIFIC-9 trial remains an important study to monitor for advancements in Stage III lung cancer care. Patients currently in treatment or managing a diagnosis should continue to follow their physician-led care plans rather than anticipating near-term changes from this ongoing trial.
Further reading
For more information on lung cancer treatment developments, visit Cancer.
Source note: This article includes information reported by Firstwordpharma.
Live Poll
Is the new 2027 timeline for the PACIFIC-9 trial likely to remain the final readout date?
